Xcout Intel
Exciva
EXCIVA GmbH is a privately held biotechnology company established in 2016 in Heidelberg, Germany, focused on developing clinical-stage therapeutics to improve quality of life and treat Alzheimer's disease.
Subscribe to see Exciva’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Exciva at a glance
Exciva is a life sciences company headquartered in Germany. Its most recent funding round, Series B, raised $59M in January 2026. Xcout tracks 16 named people at Exciva, including François Conquet (CEO).
Exciva leadership
- François ConquetCEO
- Nadine KnowlesCOO
- Francisco OrellanaCFO
- Anton BespalovCo-founder, CSO and Managing Director
- Hans J. MoebiusCo-founder and CMO
- Sreenivasarao VepacheduCo-founder and Patent Attorney
10 more named people on record for Exciva, with roles, board committees and tenure — see the full roster →
Exciva funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $59M | 10 named | |
| — | $10.4M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Exciva competitors
A few of Exciva's closest competitors — see the full list of competitors and alternatives →
Ultimate Medicine AG is a Swiss preclinical biotechnology company headquartered in Zürich, focused on maximizing the healthspan of patients with Alzheimer's disease and other dementias by targeting novel toxic metabolites.
Alzinova AB is a Swedish clinical-stage biopharmaceutical company that develops disease-modifying treatments and vaccines targeting Alzheimer's disease. Utilizing its proprietary AβCC Peptide technology, the company focuses on creating therapeutics for Alzheimer's patients to address high unmet medical needs in neurodegeneration.
Asceneuron is a biotechnology research company founded in 2012 and headquartered in Eysins, Switzerland, focusing on the discovery and development of therapeutics for neurodegenerative disorders.
Muna Therapeutics is a privately held biopharmaceutical company founded in 2020 with headquarters in Copenhagen, Denmark, and operations in Leuven. The company discovers and develops novel therapies aimed at slowing or stopping devastating neurodegenerative diseases like Alzheimer's and Parkinson's.
Probiodrug AG is a biopharmaceutical company headquartered in Halle, Germany, that aims to become a leading enterprise in its field and has previously held an initial public offering on Euronext Amsterdam. The company's focus includes addressing conditions such as Alzheimer's disease through specialized therapeutic development.
Recognify Life Sciences is a clinical-stage biotechnology company located in California, focusing on developing treatments for cognitive impairment associated with central nervous system disorders.
Get Exciva's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Exciva in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access